Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia	Carcinogenesis, Cell Transformation, Neoplastic, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, acute biphenotypic leukemia, acute myeloid leukemia, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, bone marrow disorder, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, myelodysplastic syndrome, myeloid leukemia, neoplasm, therapy related acute myeloid leukemia and myelodysplastic syndrome	Recruiting	Phase 2	2026-05-20		NCT02115295

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
M.D. Anderson Cancer Center	1145
National Cancer Institute (NCI)	3015

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
M D Anderson Cancer Center	Houston	United States	667